{
    "organizations": [],
    "uuid": "e547f61335a778ce0460288f033fb5c3083cc977",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cyclacel-pharmaceuticals-posts-qtr/brief-cyclacel-pharmaceuticals-posts-qtrly-loss-of-2-1-mln-idUSASC09U25",
    "ord_in_thread": 0,
    "title": "BRIEF-Cyclacel Pharmaceuticals Posts Qtrly Loss Of $2.1 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - Cyclacel Pharmaceuticals Inc:\n* CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* CYCLACEL PHARMACEUTICALS - ‍AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS TOTALED $23.9 MILLION, COMPARED TO $16.5 MILLION LAST YEAR\n* CYCLACEL PHARMACEUTICALS INC - NET LOSS APPLICABLE TO COMMON SHAREHOLDERS FOR THREE MONTHS ENDED DEC 31, 2017 WAS $2.1 MILLION​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)\n ",
    "published": "2018-03-29T04:15:00.000+03:00",
    "crawled": "2018-03-29T15:55:54.123+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "cyclacel",
        "pharmaceutical",
        "inc",
        "cyclacel",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "cyclacel",
        "pharmaceutical",
        "dec",
        "cash",
        "cash",
        "equivalent",
        "totaled",
        "million",
        "compared",
        "million",
        "last",
        "year",
        "cyclacel",
        "pharmaceutical",
        "inc",
        "net",
        "loss",
        "applicable",
        "common",
        "shareholder",
        "three",
        "month",
        "ended",
        "dec",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "bengaluru",
        "newsroom"
    ]
}